SAYARE MITCHEL 4

What Happened

• Sayare Mitchel, a director of Altimmune, was granted 48,800 derivative securities (reported as an award) on May 1, 2026. The filing shows $0 reported as the acquisition price (a grant), indicating no cash was paid by the insider at grant. The award was made pursuant to the company's non-employee director compensation policy.

Key Details

• Transaction date: 2026-05-01. Transaction code: A (award/grant).
• Amount: 48,800 derivative securities (options) reported as acquired for $0.
• Shares owned after transaction: not specified in this Form 4 filing.
• Footnotes: F1 — grant made under the company's non-employee director compensation policy; F2 — the shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to continued service.
• Filing timeliness: transaction and report date are the same (2026-05-01); the filing does not indicate a late report.

Context

• This is a routine director compensation award rather than a market purchase or sale. Grants to directors are commonly used as retention and alignment incentives and do not, by themselves, signal immediate buying or selling intent.
• The award is a derivative (options) with a vesting schedule; these options are not necessarily exercisable or sold immediately. The Form 4 does not disclose exercise price or fair value in this entry.